Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRI assessment of liraglutide (Victoza) for cardiovascular dysfunction in type 2 diabetes
NL-OMON44757Phase 4Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Nov 2013
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of liraglutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Leiden University Medical Center. Primary endpoints: Stroke volume, Left ventricular ejection fraction and 9 more. Started Nov 2013; status: active, not recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON44757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44757.